Biodexa Pharmaceuticals (NASDAQ:BDRX) shares surged 81.82% during regular trading hours on Thursday, climbing from a prior close of $0.66 to a session high of $1.20. Trading volume reached approximately 65.1 million shares, dramatically exceeding the stock's average daily volume of roughly 1.67 million shares.

What We Know About the BDRX Rally

Biodexa Pharmaceuticals is a United Kingdom-based clinical-stage biopharma company focused on treatments for rare diseases, including familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer, Type 1 diabetes, and orphan brain cancers. The company employs just 13 people and has a market capitalization under $1 million.

Key metrics for this session:

  • Price gain: +81.82% (from $0.66 to $1.20)
  • Session volume: ~65.1 million shares
  • Average daily volume: ~1.67 million shares
  • Days to cover short interest: 1.00
  • Short interest: 33,356 shares

Why BDRX Is Moving Today

No new news or SEC filing from Thursday's session clearly explains the dramatic move. The most recent company announcement is from August 19, 2026, when Biodexa announced a major milestone for its Serenta registrational Phase 3 trial in FAP. That news is roughly three weeks old.

Potential factors behind the move include:

  • Short squeeze dynamics: With only 1.00 days to cover and 33,356 shares sold short, a short-covering cascade could amplify upward price movements in a thinly traded stock
  • Thin trading conditions: BDRX has a float of roughly 594,060 shares and a market cap under $900,000, making it highly susceptible to sharp price swings on limited buying interest
  • Biotech sector rotation: Small-cap biotech names occasionally attract speculative trading when larger indices experience volatility

Recent Company Developments

Biodexa has several programs in its pipeline:

  • Serenta (eRapa): A registrational Phase 3 trial for familial adenomatous polyposis (FAP). The company launched a global early access program for this candidate in March 2026 through a partnership with Tanner Pharma Group
  • MTX110: A Phase 1 treatment targeting difficult brain malignancies
  • Tolimidone: A selective lyn kinase activator in Phase II trials for Type 1 diabetes
  • OPB-171775: A Phase 1-ready molecular glue targeting gastrointestinal stromal tumors (GIST), licensed from Otsuka in February 2026

The company also underwent a 1-for-10 reverse split in April 2026 and changed its ADR ratio in March 2026, common restructuring moves for micro-cap companies seeking to maintain exchange compliance.

What to Watch

Traders should monitor for any late-filing disclosures, SEC Form 8-K filings, or after-hours announcements that could explain the session's unusual activity. Given BDRX's micro-cap status and elevated short interest relative to trading volume, the stock may remain volatile even after Thursday's significant move.